Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David A Scheinberg

Showing results (111-120 of 172) with videos related to

Pageof 18
Sort By:
Cancer|September 5, 2002
A single, high dose of idarubicin combined with cytarabine as induction therapy for adult patients with recurrent or refractory acute lymphoblastic leukemiaMark A Weiss, Timothy B Aliff, Martin S Tallman, et al.
Plos One|March 8, 2007
Selective alpha-particle mediated depletion of tumor vasculature with vascular normalizationJaspreet Singh Jaggi, Erik Henke, Surya V Seshan, et al.
Science Translational Medicine|March 25, 2016
Targeted fibrillar nanocarbon RNAi treatment of acute kidney injurySimone Alidori, Nima Akhavein, Daniel L J Thorek, et al.
Cancer Immunology, Immunotherapy : CII|October 30, 2020
Impact of tumor heterogeneity and microenvironment in identifying neoantigens in a patient with ovarian cancerTao Dao, Martin G Klatt, Tatyana Korontsvit, et al.
JCI Insight|November 16, 2018
Panobinostat acts synergistically with ibrutinib in diffuse large B cell lymphoma cells with MyD88 L265P mutationsPatrizia Mondello, Elliott J Brea, Elisa De Stanchina, et al.
Cancer Immunology, Immunotherapy : CII|June 10, 2010
WT1 peptide vaccinations induce CD4 and CD8 T cell immune responses in patients with mesothelioma and non-small cell lung cancerLee M Krug, Tao Dao, Andrew B Brown, et al.
JCI Insight|March 30, 2017
Panobinostat acts synergistically with ibrutinib in diffuse large B cell lymphoma cells with MyD88 L265P mutationsPatrizia Mondello, Elliott J Brea, Elisa De Stanchina, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 8, 2006
Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemiaNicole Lamanna, Matt Kalaycio, Peter Maslak, et al.
Blood Advances|May 13, 2022
Unmasking the suppressed immunopeptidome of EZH2-mutated diffuse large B-cell lymphomas through combination drug treatmentChristopher M Bourne, Sung Soo Mun, Tao Dao, et al.
Blood|January 25, 2023
Potentiating antibody-dependent killing of cancers with CAR T cells secreting CD47-SIRPα checkpoint blockerMegan M Dacek, Keifer G Kurtz, Patrick Wallisch, et al.
Pageof 18

Showing results (111-120 of 172) with videos related to

Sort By:
Pageof 18
Cancer|September 5, 2002
A single, high dose of idarubicin combined with cytarabine as induction therapy for adult patients with recurrent or refractory acute lymphoblastic leukemiaMark A Weiss, Timothy B Aliff, Martin S Tallman, et al.
Plos One|March 8, 2007
Selective alpha-particle mediated depletion of tumor vasculature with vascular normalizationJaspreet Singh Jaggi, Erik Henke, Surya V Seshan, et al.
Science Translational Medicine|March 25, 2016
Targeted fibrillar nanocarbon RNAi treatment of acute kidney injurySimone Alidori, Nima Akhavein, Daniel L J Thorek, et al.
Cancer Immunology, Immunotherapy : CII|October 30, 2020
Impact of tumor heterogeneity and microenvironment in identifying neoantigens in a patient with ovarian cancerTao Dao, Martin G Klatt, Tatyana Korontsvit, et al.
JCI Insight|November 16, 2018
Panobinostat acts synergistically with ibrutinib in diffuse large B cell lymphoma cells with MyD88 L265P mutationsPatrizia Mondello, Elliott J Brea, Elisa De Stanchina, et al.
Cancer Immunology, Immunotherapy : CII|June 10, 2010
WT1 peptide vaccinations induce CD4 and CD8 T cell immune responses in patients with mesothelioma and non-small cell lung cancerLee M Krug, Tao Dao, Andrew B Brown, et al.
JCI Insight|March 30, 2017
Panobinostat acts synergistically with ibrutinib in diffuse large B cell lymphoma cells with MyD88 L265P mutationsPatrizia Mondello, Elliott J Brea, Elisa De Stanchina, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 8, 2006
Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemiaNicole Lamanna, Matt Kalaycio, Peter Maslak, et al.
Blood Advances|May 13, 2022
Unmasking the suppressed immunopeptidome of EZH2-mutated diffuse large B-cell lymphomas through combination drug treatmentChristopher M Bourne, Sung Soo Mun, Tao Dao, et al.
Blood|January 25, 2023
Potentiating antibody-dependent killing of cancers with CAR T cells secreting CD47-SIRPα checkpoint blockerMegan M Dacek, Keifer G Kurtz, Patrick Wallisch, et al.
Pageof 18